gutsandgrowth

Home | About Jay Hochman -Pediatric Gastroenterology Blog | Archives

“For Hospitalized Patients With ASUC, 5-ASA Adds No Value to Steroids”

May 5, 2022 7:00 am

From Gastroenterology and Endoscopy News (4/25/22): Open Access: For Hospitalized Patients With ASUC, 5-ASA Adds No Value to Steroids

In the first prospective randomized study, presented at the 2022 Crohn’s & Colitis Congress and published in Inflammatory Bowel Dis (S Ben-Horin et al 2022;28 [suppl 1]:S14 CORTICOSTEROIDS AND 5ASA VERSUS CORTICOSTEROIDS ALONE FOR ACUTE SEVERE ULCERATIVE COLITIS: A RANDOMIZED CONTROLLED TRIAL), investigators at 10 centers in six countries randomly assigned 149 patients hospitalized for ASUC to receive daily doses of 300 mg of hydrocortisone (or equivalent methylprednisolone) alone or in combination with 4 g of mesalamine.

Key findings:

• 72.6% of patients receiving combination corticosteroids with 5-ASA responded to treatment at one week compared with 76.3% of responders in the group receiving corticosteroids alone
• “There were no differences in hospital length of stay between groups (median, 10 vs. nine days for the combination and monotherapy groups, respectively), the proportion of patients whose C-reactive protein level normalized (34.2% vs. 34.3%, respectively), or the proportion requiring colectomy within 90 days (4.9% vs. 4.5%, respectively).”
• While 5-ASAs did not alter the trajectory of acute colitis, one other finding was a lower rate of biologic use (27% vs 47%, P=.07) at 90 days in those who continued to receive 5-ASA therapy at 90 days.

My take: 5-ASAs do not appear to be helpful during hospitalization for ASUC but may be beneficial as a maintenance therapy in some patients.

Related blog posts:

• Early Assessment of Acute Ulcerative Colitis with ACE (Albumin, CRP, & Endoscopy)
• Management of Acute Severe Colitis
• AGA Guidelines: Moderate to Severe Ulcerative Colitis
• A Definite Maybe: Antibiotics for Acute Severe Colitis
• Management of Acute Severe Ulcerative Colitis
• Oral Antibiotics For Refractory Inflammatory Bowel Disease | gutsandgrowth
• Management of Pediatric Ulcerative Colitis -ECCO Recommendations
• An Overlooked Finding in A Recent Severe Colitis Study
• Infliximab for children with Ulcerative Colitis
• Accelerated Infliximab Dosing in Acute … – gutsandgrowth
• Predictors of colectomy in pediatric UC | gutsandgrowth

Disclaimer: This blog, gutsandgrowth, assumes no responsibility for any use or operation of any method, product, instruction, concept or idea contained in the material herein or for any injury or damage to persons or property (whether products liability, negligence or otherwise) resulting from such use or operation. These blog posts are for educational purposes only. Specific dosing of medications (along with potential adverse effects) should be confirmed by prescribing physician.  Because of rapid advances in the medical sciences, the gutsandgrowth blog cautions that independent verification should be made of diagnosis and drug dosages. The reader is solely responsible for the conduct of any suggested test or procedure.  This content is not a substitute for medical advice, diagnosis or treatment provided by a qualified healthcare provider. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a condition

Posted by gutsandgrowth

Categories: inflammatory bowel disease

Tags: 5-ASA, acute severe ulcerative colitis, mesalamine, Ulcerative colitis

« Older Newer »

Mobile Site | Full Site

Get a free blog at WordPress.com Theme: WordPress Mobile Edition by Alex King.